Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVEC-R chemo-resection vs standard treatment in NMIBC
2014-005001-20Phase 3Active
- Sponsor
- Dr. Alejandro Sousa Escandón
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Dr. Alejandro Sousa Escandón. Primary endpoint: Disease-free survival rate at 24 months. Started Mar 2015; status: active.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2014-005001-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005001-20.